Multimodal Imaging Evaluation and Prognostic Analysis of Participants After Arterial Switch Operation
Launched by XIE MINGXING · Jul 26, 2021
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand how the Arterial Switch Operation (ASO) affects patients with specific heart conditions, particularly those with Transposition of the Great Arteries (TGA) or Total Anomalous Pulmonary Venous Return (TBA). The study aims to find out how well patients do after the surgery, including any serious issues like death or the need for another surgery. Researchers also want to see how different heart artery problems might affect recovery and if there are any signs that could predict future heart valve issues or narrowing of the pulmonary arteries after the operation.
To participate in this trial, patients must have been diagnosed with TGA or TBA and have undergone the ASO surgery. Unfortunately, those who have had other specific heart surgeries related to TGA will not be eligible. Participants will be monitored closely to gather information about their health outcomes following the surgery. This study is an important step in improving care and understanding for patients who undergo this complex procedure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ·Participants with the diagnosis of TGA or TBA underwent ASO.
- Exclusion Criteria:
- • Patients with various forms of TGA undergoing Réparation à l'Etage Ventriculaire procedure
- • Patients with various forms of TGA undergoing Rastelli procedure
- • Patients with various forms of TGA undergoing Nikaidoh procedure
- • Patients with various forms of TGA undergoing Fontan operation
- • Patients with various forms of TGA undergoing atrial repair (Mustard or Senning) operations
- • ASO is used as a corrective therapy for prior operations.
About Xie Mingxing
Xie Mingxing is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing cutting-edge therapies and treatments, the organization collaborates with leading healthcare professionals and institutions to conduct rigorous clinical trials. Xie Mingxing prioritizes patient safety and ethical research practices, ensuring that all trials adhere to the highest standards of quality and regulatory compliance. Through its strategic approach and commitment to scientific excellence, Xie Mingxing aims to contribute significantly to the improvement of healthcare outcomes and the development of new medical solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Li Zhang, PhD
Principal Investigator
Department of Ultrasound, Union Hospital, Wuhan, China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials